Introduction
Studies of oncogenic signaling pathways in human cancers have identified molecular targets for developing rationally-designed cancer therapeutics. In particular, many receptor and non-receptor tyrosine kinases, including EGF receptor (EGR-R), Her-2/Neu, JAK and Src are found to be constitutively-activated in various cancers (Catlett-Falcone et al., 1999b; Ciardiello and Tortora, 2001; Garcia et al., 2001; Grandis et al., 2000; Irby and Yeatman, 2000; Levitzki, 1999; Mendelsohn and Baselga, 2000, Meydan et al., 1996; Staley et al., 1997) . Targeting these signaling pathways in certain cancers has generated promising results both in preclinical studies and in human clinical trials (Ciardiello and Tortora, 2001; Irby and Yeatman, 2000; Levitzki, 1999; Mendelsohn and Baselga, 2000; Meydan et al., 1996; Moasser et al., 1999; Staley et al., 1997) . Significantly, many of these oncogenic tyrosine kinases transmit signals through the signal transducer and activator of transcription 3 (Stat3) protein Bromberg and Darnell, 2000; Bromberg et al., 1999; Catlett-Falcone et al., 1999a,b; Grandis et al., 1998 Grandis et al., , 2000 Song and Grandis, 2000; Yu et al., 1995) .
As a point of convergence for many oncogenic tyrosine kinase signaling pathways, such as EGF-R, IL-6/JAK and Src, Stat3 has been found to be activated at very high frequency in diverse cancer cell lines and tumor tissues, including breast cancer, head and neck squamous cell carcinoma, prostate cancer, various leukemias and multiple myeloma Bromberg and Darnell, 2000; Bromberg et al., 1999; Buettner et al., 2002; Catlett-Falcone et al., 1999a,b; Grandis et al., 1998; Reddy et al., 2000) . Furthermore, accumulating evidence is defining a critical role for Stat3 in oncogenesis Bromberg and Darnell, 2000; Bromberg et al., 1999; Catlett-Falcone et al., 1999a,b; Grandis et al., 2000; Song and Grandis, 2000) . In particular, Stat3 signaling has been shown to prevent programmed cell death and enhance cell proliferation through regulating genes involved in cell growth and apoptosis, including Bcl-x L , Mcl-1, c-Myc and cyclin D1 Bromberg et al., 1999; Catlett-Falcone et al., 1999b; Epling-Burnette et al., 2001; Grandis et al., 2000; Sinibaldi et al., 2000) . In addition to its role in promoting tumor cell growth and survival, constitutive Stat3 activation has also been shown to up-regulate VEGF expression and to promote tumor angiogenesis . These results, taken together, suggest that constitutive activation of Stat3 has a critical role in the pathogenesis and progression of diverse human cancers.
Numerous studies have also demonstrated that abrogation of Stat3 signaling blocks oncogenesis in vitro and in vivo Bromberg et al., 1998; Buettner et al., 2002; Catlett-Falcone et al., 1999b; Garcia et al., 2001; Grandis et al., 1998 Grandis et al., , 2000 Niu et al., 1999; Turkson et al., 1998 Turkson et al., , 2001 . Interrupting Stat3 signaling has been shown to induce tumor apoptosis and/or cell cycle arrest in a wide range of cancer cell lines, including multiple myeloma, head and neck squamous cell carcinoma, prostate cancer and breast cancer . In IL-6-dependent human myeloma cells, interrupting IL-6 receptor, JAK or Stat3 signaling inhibits Bcl-x L expression and induces apoptosis (Catlett-Falcone et al., 1999b) . Disrupting Stat3 signaling in head and neck cancer cells attenuates EGF-R-mediated tumor growth and induces apoptosis (Grandis et al., 1998 . Inhibition of JAK, Src, or Stat3 signaling in breast cancer cells leads to cell cycle arrest and apoptosis of tumor cells (Garcia et al., 2001) . Our earlier studies using gene therapy targeting Stat3 in the murine B16 melanoma model demonstrate that blocking Stat3 in vivo causes tumor regression accompanied by apoptosis (Niu et al., 1999) . Other recent studies have also provided data indicating that targeting Stat3 in tumors can inhibit tumor growth in vivo Ni et al., 2000) .
Delineation of oncogenic signaling pathways involving tyrosine kinases and Stat3 in a variety of human cancers has provided the rationale for designing new drugs for these cancers (Ciardiello and Tortora, 2001; Mendelsohn and Baselga, 2000; Turkson and Jove, 2000) . However, little is known about the oncogenic signaling pathways critical for tumor growth and survival in many other malignancies, including melanoma. Malignant melanoma is a solid tumor that has increased in incidence at a rate of 4% per year over the last two decades. Melanoma frequently metastasizes through lymph nodes, making it not amenable to surgical treatment. Because melanoma is often resistant to systemic treatment with currently available chemotherapy and radiotherapy, it is important to identify molecular targets that are critical for melanoma cell growth and survival. Our current study demonstrates that Stat3 is constitutively activated in a majority of human melanoma cell lines and tumor specimens. Furthermore, Src tyrosine kinase inhibitors disrupt Stat3 DNA-binding activity and induce tumor cell death. Moreover, directly blocking Stat3 DNAbinding by a dominant-negative Stat3 protein leads to melanoma cell apoptosis. These findings suggest that targeting Stat3 and/or Src may represent a novel therapy for melanoma.
Results

Stat3 is constitutively activated in human melanoma cell lines
Our previous studies demonstrated that Stat3 activity is essential for the growth and survival of murine melanoma B16 cells (Niu et al., 1999 . To determine whether constitutive STAT signaling may be involved in controlling growth of human melanoma cells, we examined STAT DNA-binding activity in a panel of human melanoma cell lines by EMSA using the radiolabeled hSIE probe, which binds to activated Stat1 and Stat3 (Turkson et al., 1998) . As shown in Figure 1a , constitutive STAT DNA-binding activity was detected to different extents in nuclear extracts prepared from a majority of human melanoma cell lines examined (16 out of 18). Constitutive hSIEbinding activity in these nuclear extracts from melanoma cells was specifically competed by unlabeled hSIE but not by an irrelevant oligonucleotide ( Figure  1b) . To identify the STAT family members activated in the melanoma cells, supershift assays with Stat1, Stat3 or Stat5 specific antibodies were performed using nuclear extracts of A2058 or JW melanoma cells. As shown in Figure 1b , the complexes were specifically supershifted by Stat3 antibody but not by Stat1 or Stat5 antibodies, indicating Stat3 activation in every case.
Activation of Stat3 in human primary tumor specimens
We next investigated whether constitutive activation of Stat3 also occurs in tumor specimens from melanoma patients. Nuclear extracts prepared from normal skin and primary tumor tissues were incubated with the 32 P-labeled hSIE oligonucleotide probe and analysed by EMSA. In contrast to normal skin samples which had none or little STAT DNA-binding activity, many of the primary tumor tissues displayed elevated STAT DNA-binding activity to different extents. The specificity of STAT DNA-binding and identity of the STAT family member activated in two of the primary tumor tissues were determined by competition and supershift EMSAs (Figure 2b) . Results from the competition and supershift EMSAs confirmed that Stat3, and to a lesser degree Stat1, was activated in primary melanoma tissues. Activated Stat3 was present as both Stat3 : Stat3 homodimers and Stat1 : Stat3 heterodimers.
Src kinase activity is required for Stat3 constitutive activation in melanoma cells
Several receptor and non-receptor tyrosine kinase signaling pathways, including Src, EGF-R and JAK, are known to activate Stat3 Catlett-Falcone et al., 1999b; Grandis et al., 1998 Grandis et al., , 2000 Yu et al., 1995) . To determine which tyrosine kinase signaling pathways might be responsible for Stat3 activation in melanoma cells, we examined the effects of a panel of tyrosine kinase inhibitors on Stat3 DNA-binding activity in melanoma cell lines. To assess if JAKs are involved in Stat3 activation in melanoma cells, a selective inhibitor of JAK family kinases, the tyrphostin AG490 (Catlett-Falcone et al., 1999b; Meydan et al., 1996) , was used to determine its ability to inhibit Stat3 DNA-binding in two melanoma cell lines, A2058 and JW. These two cell lines display intermediate (A2058) and high (JW) levels of Stat3 DNA-binding activity, respectively (Figure 1 ). Little or no inhibition of Stat3 DNA-binding was observed when increasing concentrations of AG490 were used to treat the two melanoma cell lines (data not shown). Even in the presence of 50 mM AG490, which was the highest concentration used to disrupt Stat3 DNAbinding activity and induce apoptosis in previous studies (Catlett-Falcone et al., 1999b; Meydan et al., 1996) , no significant attenuation of Stat3 DNA-binding was observed (Figure 3a ,b). We next tested if blocking EGF-R kinase signaling by the selective inhibitor, PD158780, was able to block Stat3 DNA-binding in these cells. Again, no disruption of Stat3 DNA-binding was observed at the highest concentration (500 nM) (Figure 3a ,b) used in previous studies (Garcia et al., 2001) . In contrast to JAK and EGF-R inhibitors, two other tyrosine kinase inhibitors, PD166285 and PD180970 , were able to inhibit Stat3 DNA-binding in a dose-dependent manner in the melanoma cell lines. While PD166285 has broad specificity for various tyrosine kinases including Src, PD180970 is selective for Src and Bcr-Abl kinases (Dorsey et al., 2000; Kraker et al., 2000) .
To confirm that Src was activated in the melanoma cell lines, Western blot analyses using either a c-Src antibody or an antibody to detect phosphorylated Src residue Tyrosine 419 (the site of autophosphorylation in activated Src) were performed. Figure 3c shows that while all the three melanoma cell lines express c-Src protein, the extent of phosphorylated Src kinase correlated well with both Src expression and Stat3 DNA-binding activity (compare with Figure 1a ). When the band intensities of phosphorylated c-Src protein and Stat3 DNA-binding were compared among the three melanoma cell lines, a coefficiency of 0.999 with P=0.026 was obtained. Furthermore, although none of the tyrosine kinase inhibitors affected c-Src expression at the protein level, both Src kinase inhibitors significantly reduced phosphorylated Src protein ( Figure 3c ). By contrast, neither the JAK nor EGF-R inhibitor was able to affect Src phosphorylation. Taken together, these results suggest that activated Src kinase P-labeled hSIE oligonucleotide probe and analysed by EMSA. Antibody super-shifting EMSA: nuclear extracts pre-incubated with Stat1, Stat3 or Stat5 specific antibodies were reacted with 32 P-labeled hSIE. hSIE=high-affinity sis-inducible element (m67 variant of the Stat3-binding site in the c-fos promoter) (Wagner et al., 1990) ; FIRE=an irrelevant oligonucleotide (Turkson et al., 1998) . The asterisk indicates position of antibody-shifted Stat3 protein mediates constitutive Stat3 activation in human melanoma cells.
Inhibiting Src activity blocks growth of human melanoma cell lines with elevated Stat3 activity
We examined the effect of JAK inhibitor (AG490), EGF-R inhibitor (PD158780), as well as Src inhibitors (PD166285, PD180970) on growth of human melanoma cells. As shown in Figure 4a , none of the inhibitors had dramatic effects on the growth of SK-Mel-28 cells, which display very low Src activity and Stat3 DNAbinding activity (Figure 1 ). AG490 at high dose (50 mM) partially inhibited the growth of SK-Mel-28, A2058 and JW cells. High dose (500 nM) of PD158780 had no effects on the growth of any of these cells. By contrast, treatment with PD166285 or PD180970 resulted in a dose-dependent growth inhibition of the A2058 and JW melanoma cells with activated Stat3. Importantly, the growth inhibition resulting from PD166285 and PD180970 treatment correlated with reduced Stat3 DNA-binding activity (Figure 3) . However, treatment with PD166285 and PD180970 had only partial effects on growth of the SK-Mel-28 cell line. The effects of the various tyrosine kinase inhibitors on the viability of melanoma cells are shown in Figure 4b . These results suggest that c-Src kinase activity is critical to growth regulation of human melanoma cells.
Blocking Src activity induces apoptosis of human melanoma cells
To investigate survival regulation by Src tyrosine kinase in human melanoma cells, we examined the effects of PD166285 and PD180970 on apoptosis of these cells using Annexin V-PE staining analysed by FACS as an early indicator of apoptosis. As shown in Figure 5 , treatment with these compounds had small effects on apoptosis of SK-Mel-28 cells (top panel), which displays little Src and Stat3 activity. By contrast, treatment with the Src inhibitors significantly increased apoptosis in A2058 (middle panel) and JW (lower panel) cells. These results indicate that Src tyrosine kinase is critical for survival of human melanoma cells with constitutively-activated Stat3.
Disrupting Stat3 signaling in A2058 and JW melanoma cells induces apoptosis
To determine whether Src-dependent melanoma cell growth requires Stat3 signaling, an expression vector encoding a dominant-negative variant of Stat3, designated Stat3b (pIRES-EGFP-Stat3b, or pIRESStat3b for short), was transiently transfected into A2058 and JW cells. A control empty vector encoding green fluorescent protein alone (pIRES-EGFP) was also transfected into these cell lines as a negative control. The transfection efficiencies of the two vectors Figure 6a) . However, the numbers of viable A2058 and JW cells decreased dramatically 48 h later in the Stat3b-transfected population (Figure 6a ) when compared to those that received the control empty vector. We next measured the effects of interrupting Stat3 signaling on the clonal growth of A2058 cells by enforcing Stat3b expression. Stable co-transfection of pIRES-EGFP with either pcDNA-hyg plasmid or pcDNA-hyg-Stat3b expression vector into A2058 cells was carried out. Transfected cells were selected with hygromycin for 14 days. While the transfection efficiency of the two groups within each experiment was similar 24 h post-transfection (Figure 6b ), the numbers of colonies that survived hygromycin selection in Stat3b-transfected and the control empty vectortransfected A2058 cells were clearly different (control=25 colonies, Stat3b=5 colonies) 2 weeks later ( Figure 6b ).
To determine if disrupting Stat3 signaling in the melanoma cells would result in apoptosis, transfected cells were stained with Annexin V-PE, followed by FACS analysis. As shown in Figure 6c , more apoptotic cells were detected in Stat3b-transfected cells (52.2%) than that of empty vector-transfected cells (24.6%). Thus, at any given time, there are at least twofold more cells undergoing apoptosis when Stat3b is expressed. These results demonstrate that directly blocking Stat3 signaling induces apoptosis of melanoma cells.
Interrupting Src and Stat3 signaling inhibits expression of the anti-apoptotic genes, Bcl-x L and Mcl-1
We next determined whether disrupting Stat3 signaling with either tyrosine kinase inhibitors, PD166285, and PD180970, or dominant-negative Stat3 protein would change the expression of genes involved in regulation of apoptosis. RNAse protection assays (RPA) using a multi-probe template specific for key physiological regulators of apoptosis revealed that treating JW and A2058 melanoma cell lines with either of the two Src inhibitors dramatically down-regulated expression of Bcl-x L and Mcl-1 (Figure 7a) . Furthermore, transient transfection of the two melanoma cell lines with the Stat3b expression vector resulted in a down-regulation of these two anti-apoptotic genes at both the RNA (Figure 7b ) and protein levels (Figure 7c ). While only approximately 40% of the cells were transfected based on the fraction of cells that were fluorescent (data not shown), a significant reduction in the expression of these genes was observed as indicated by the quantification of band intensities (right panels of Figure 7b ,c).
Discussion
Our findings demonstrate that Stat3 is constitutively activated in a majority of melanoma cell lines and tumor tissues. Moreover, c-Src, but not EGF-R or JAK tyrosine kinases, is responsible for Stat3 activa- Figure 3 Src tyrosine kinase activity, but not EGF-R or JAK activity, contributes to constitutive activation of Stat3 in melanoma cells. (a) and (b) The broad-specificity tyrosine kinase inhibitor PD166285, and the Src-selective inhibitor PD180970, abrogate Stat3 DNA-binding activity in melanoma cells in a concentration-dependent manner as measured by EMSA. (c) Src is activated in the melanoma cells and treatment with either of the two Src inhibitors diminished the levels of activated Src in these cells. Western blot analyses of total proteins prepared from the indicated melanoma cell lines were performed using either an antibody to total c-Src protein or an antibody to detect phosphorylated Tyr419 in activated Src. Treatment of cells with DMSO (vehicle) or inhibitors of JAKs (AG490) or EGF-R (PD158780) had no effects on Stat3 activity of Src kinase tion in the melanoma cell lines examined. Our results also demonstrate that disrupting Stat3 signaling by either inhibitors of Src tyrosine kinase activity or dominant-negative Stat3 induces apoptosis of melanoma cells and down-regulates expression of the Bcl-x L and Mcl-1 genes. While Stat1 is activated in some tumor tissues, previous studies have demonstrated that Stat1 is not involved in oncogenesis Bromberg and Darnell, 2000) . In particular, blocking Stat3 but not Stat1 resulted in tumor cell apoptosis (Grandis et al., 1998; Shen et al., 2001) . These findings suggest critical roles for Src and Stat3 signaling in melanoma survival and malignant progression.
Many tyrosine kinases involved in growth factor and cytokine signaling as well as oncogene-encoded tyrosine kinases have been shown to activate Stat3 in diverse types of cancer cells Bromberg and Darnell, 2000; Bromberg et al., 1999; Catlett-Falcone et al., 1999a,b; Grandis et al., 2000; Yu et al., 1995) . The role of Stat3 in growth factor receptor signaling-mediated oncogenesis has been extensively investigated in head and neck cancer and breast carcinoma. Compared to normal mucosal epithelial cells, human head and neck carcinoma cells overexpress both TGF-a and its cognate receptor, EGF-R. It has been shown that TGF-a/EGF-Rmediated growth of transformed epithelial cells requires Stat3 signaling (Grandis et al., 1998 . Moreover, disrupting Stat3 signaling abrogates TGF-ainduced proliferation of these cells (Grandis et al., 1998 . Similarly, constitutive activation of Stat3 in human breast cancer cells is vital for their survival (Garcia et al., 1997 (Garcia et al., , 2001 ). Furthermore, it has been shown in the breast cancer cells that JAK and Src signaling pathways collaborate with EGF-R in Stat3 activation and tumor cell survival (Garcia et al., 1997 (Garcia et al., , 2001 ). In melanoma cells, an earlier study indicated a role of a Src-family kinase in bFGF-mediated melanoma cell proliferation (Yayon et al., 1997) . However, whether c-Src activity contributed to melanoma proliferation and tumorigenesis was not determined (Yayon et al., 1997) . Our results demonstrate a critical role of activated c-Src in melanoma cell survival. While aberrant activation of Src in a wide range of cancers has been demonstrated (Irby and Yeatman, 2000) , multiple tyrosine kinase signaling pathways can be engaged in activating Stat3 in the same transformed cell as seen in the breast cancers (Garcia et al., 2001) . Activation of EGF-R or Her-2 has been demonstrated to activate c-Src and JAK (Buettner et al., 2002; Karni et al., 1999) . In contrast to (Garcia et al., 2001) , inhibition of JAK signaling did not affect melanoma cell survival. Although we cannot rule out the possibility that EGF-R and JAK or other signaling pathways participate in Stat3 activation in some melanoma cell lines, we show that directly targeting Stat3, which is constitutively activated in a majority of While PD180970 inhibits both Src and Bcr-Abl kinases, there is no evidence that Bcr-Abl has any role in malignant progression of melanoma. Furthermore, although PD166285 has broad-specificity for other tyrosine kinases, it is a potent inhibitor of Src kinase. Thus, the common target for both PD180970 and PD166285 is Src kinase, consistent with their abilities for effectively inhibit c-Src autophosphorylation in vivo (Figure 3c ). Our study demonstrates that targeting either c-Src or Stat3 leads to inhibition of melanoma cell growth and Bcl-x L and Mcl-1 expression. Because Src activity is known to activate other oncogenic signaling pathways in addition to Stat3, targeting Src may inhibit multiple oncogenic pathways, leading to more potent anti-tumor effects. On the other hand, since inhibitors of tyrosine kinases including Src block more than one downstream signaling pathway, the likelihood of undesirable toxicity also increases. Further experiments are required to determine the efficacy and toxicity of targeting of Src and Stat3 for potential melanoma treatment.
In tumor cells in which Stat3 signaling is required for proliferation and survival, up-regulation of pro-growth genes, including Bcl-x L , Mcl-1, cyclin D1 and c-Myc, has been reported Bromberg et al., 1999; Catlett-Falcone et al., 1999b; Epling-Burnette et al., 2001; Grandis et al., 2000; Sinibaldi et al., 2000) . We show here that disrupting the Src-Stat3 signaling pathway down-regulates Bcl-x L and Mcl-1 expression, suggesting that Stat3 activity in melanoma cells promotes growth at least in part by enhancing expression of anti-apoptotic genes. Inhibition of c-Src kinase activity has been shown previously to downregulate Bcl-x L expression in cells overexpressing EGF-R and Her2 (Karni et al., 1999) . However, the link between Src activity and Mcl-1 expression has not been demonstrated before. Furthermore, previous studies have shown that Mcl-1 represents a survival factor for hematopoietic cells (Zhou et al., 1997) and is regulated by JAK-induced Stat3 activity in leukemic large granular lymphocytes and by Bcr-Abl-induced Stat5 in CML cells (Epling-Burnette et al., 2001; . Our results suggest that Stat3 signaling induced by c-Src activity in the absence of JAK activity in cells derived from solid tumors up-regulates Mcl-1 expression. Taken together, our results have delineated an oncogenic signaling pathway in human melanoma cells and identified novel molecular targets, including Src and Stat3, for potential melanoma therapy.
Materials and methods
Cell lines and cell culture
A total of 18 human melanoma cell lines were used for the analysis of Stat3 DNA-binding activity. Cell lines K179, 729, 1102, 1286, 1287, 1357, 1379 and WM9 were kindly provided by Dr George Blanck (University of South Florida). Cell lines 1322, 1326, 1336, JW, and JKR were established at The University of Michigan Medical School. The melanoma cell lines, 586 and 888, were generous gifts of Dr Suzanne Topalian of the National Cancer Institute. SK-Mel-28 and A2058 were obtained from ATCC. WM9 cells were maintained in MCD 153 : L15 (4 : 1) medium supplemented with 10% FBS and 5 mg/ml insulin. The SK-Mel-28 cell line was cultured in Eagle's MEM supplemented with 10% FBS. RPMI supplemented with 10% FBS was used for culturing all of the other cell lines.
Human tissues and preparation of nuclear extracts
Both normal skin and primary tumor specimens were obtained from patients undergoing surgery at the Cutaneous Oncology Program, H Lee Moffitt Cancer Center & Research Institute with appropriate informed consent from patients enrolled on protocols approved by the local Institutional Review Board. Preparation of nuclear extracts from both primary tissues and cell lines was performed as previously described (Catlett-Falcone et al., 1999b; Garcia et al., 2001) .
Electrophoretic mobility shift assay (EMSA)
Stat3 DNA-binding assays were performed as described previously (Garcia et al., 1997; Yu et al., 1995) . Briefly, nuclear extracts (1 -8 mg of total protein), normalized for protein concentration, were incubated with the 32 P-radiolabeled hSIE (high-affinity Sis-Inducible Element) oligonucleotide probe. Protein-DNA complexes were resolved by 5% non-denaturing polyacrylamide gel electrophoresis (PAGE) and specific STAT/DNA complexes were detected by autoradiography. Identification of specific STAT family member/DNA complexes was determined by competition and supershift EMSAs as previously described (Garcia et al., 1997; Yu et al., 1995) .
Treatment of melanoma cells with tyrosine kinase selective inhibitors
The JAK inhibitor AG490 (Levitzki, 1999) , the EGF-R inhibitor PD158780 (Fry, 1999) , the broad-specificity tyrosine kinase inhibitor PD166285 , and the Src selective inhibitor PD180970 have been described (Dorsey et al., 2000; Kraker et al., 2000) . Compounds were dissolved in 100% dimethyl sulphoxide (DMSO) and stored at 7808C. The stocks were diluted into the media immediately prior to use.
Plasmid DNA transfections
Transfection of melanoma cells was performed using Lipofectamine (Life Technologies, Inc.) according to the manufacturer's protocol. To determine transfection efficiency, fluorescence intensities of cells transfected with either pIRES-EGFP or pIRES-Stat3b were measured by FACS 24 h after transfection. For stable transfections, 2610 5 of A2058 cells/ 60 mm plate were co-transfected with pIRES-EGFP and pcDNA-hygromycin (hyg) (1 : 5) or pIRES-EGFP and pcDNA-hyg-Stat3b (1 : 5). Twenty-four hours later, transfection efficiencies were determined by the percentage of cells that were fluorescent. The transfected cells were then cultured in medium supplemented with hygromycin (300 mg/ml) for 14 days. The transfected cells were than stained with Giemsa solution to facilitate counting the surviving colonies.
Apoptosis assays
Following treatment with DMSO (vehicle), AG490, PD158780, PD166285, or PD180970, melanoma cells were stained with Annexin V-PE (PharMingen, San Diego, CA, USA), followed by FACS analysis using CELLQuest software as previously described (Catlett-Falcone et al., 1999b) .
Cell lysis and Western blot analysis
Cells were lysed in buffer composed of 50 mM Tris, pH 7.4, 5 mM EDTA, 150 mM NaCl, and 0.5% Triton X-100 containing 1 mg/ml leupeptin and aprotinin, and 1 mM PMSF. Protein content of cell lysates was quantified using the Bradford assay, and equal amounts of total cellular protein were dissolved in Laemmli SDS -PAGE sample buffer prior to separation by 10% SDS -PAGE. Protein was electrophoretically transferred to PVDF membrane, and Western blot analysis was done by standard techniques with ECL detection. The pTyr419-Src antibody used for immunoblotting was a generous gift from Dr Andrew Laudano of University of New Hampshire (Laudano and Buchanan, 1986) .
RNA isolation and RNase protection assays
Total RNA isolation and RNase protection assays (RPA) were carried out as previously described . Briefly, the multi-probe template, PharMingen Riboquant hAPO-2c (including probes for Bcl-w, Bcl-x L , Bcl-x S , Bfl-1, Bad, Bik, Bak, Bax, Bcl-2 and Mcl-1 genes), was synthesized by in vitro transcription with incorporation of [ 32 P-a]UTP and purified on a G50 Sephadex column (5-Prime to 3-Prime, Boulder, CO, USA). Specific activity was quantified in a Beckman LS 6500 scintillation counter (Beckman, Schaumburg, IL, USA). Purified probe (1.0 -1.5610 6 c.p.m./ml) was hybridized with 10 mg of total RNA for 16 h, followed by RNase digestion at 378C.
